Breast Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with breast cancer confirmed by a tissue sample (biopsy or surgery)
- People younger than 40 years with any type of breast cancer, or people aged 40 to 70 years with specific breast cancer subtypes, including lobular carcinoma, Luminal B HER2-positive, hormone receptor-negative and HER2-positive, or triple-negative breast cancer (TNBC)
- People who have signed a consent form agreeing to take part in the trial
- People whose cancer is at a specific stage — not too small and not too advanced locally (clinical stage T1–T3, with any lymph node status up to N3)
- People whose surgery removed the tumour with clear edges, meaning the border between the tumour and healthy tissue is at least 0.2 cm wide
- People whose cancer has not spread to other parts of the body, confirmed within the past 3 months
- People who are generally well enough to carry out daily activities (confirm with trial site for the specific fitness level required)
- People who have not previously had radiation therapy to the chest area
- Women who are able to become pregnant and are using contraception that was started during cancer treatment
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose breast cancer has certain lower-risk features (specifically Luminal A, or Luminal B HER2-negative, and aged 40 or over) and who are being considered for partial breast radiation only
- People who have had a mastectomy (full breast removal)
- People whose cancer is found in more than one separate area of the breast (multicentric tumours)
- People whose surgical margins are too close or not clear (less than 0.2 cm between the tumour and the edge of the removed tissue)
- People who are known to carry a BRCA1 or BRCA2 gene mutation (this only applies if testing has already been done)
- People with serious ongoing illnesses affecting their overall health
- People with mental health conditions or other difficulties that would prevent them from being able to sign a consent form
- People who have previously had another invasive cancer — unless it was a non-melanoma skin cancer, or unless they have been free of that cancer for at least 3 years (some early-stage cancers such as carcinoma in situ of the mouth or bladder may be considered — confirm with trial site)
- People with certain autoimmune or connective tissue diseases, such as lupus, rheumatoid arthritis, scleroderma, or Sjögren's syndrome
- People whose cancer has already spread to distant parts of the body (known as M1 or distant metastases)
- People for whom systemic (whole-body) treatment is not medically suitable (confirm with trial site)
- People who are pregnant
- People whose treatment plan cannot meet the required radiation dose safety limits (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andrei Fodor, MD, IRCCS San Raffaele Scientific Institute
Phone: +390226437634
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Local Relapse Free Survival (LRFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.